<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00826449</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0353</org_study_id>
    <secondary_id>NCI-2012-01653</secondary_id>
    <nct_id>NCT00826449</nct_id>
  </id_info>
  <brief_title>Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Phase I-II Study of Dasatinib and Erlotinib in Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>OSI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the Phase I portion of this study is to find the highest tolerable dose of the
      combination of dasatinib and erlotinib hydrochloride that can be given to patients with
      advanced solid tumors.

      The goal of the Phase II portion of this study is to learn if this combination is effective
      when given to patients with non-small cell lung cancer.

      The safety of this combination will be studied in both phases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:

      Dasatinib is designed to decrease the activity of one or more proteins that are responsible
      for the uncontrolled growth of tumor cells. This may cause the tumor cells to die.

      Erlotinib hydrochloride is designed to block the activity of a protein found on the surface
      of many tumor cells. Blocking the protein may control tumor growth and survival. This may
      stop tumors from growing.

      Study Groups:

      If you are found to be eligible to participate in this study, you will be assigned to a study
      group based on when you joined this study. Up to 6 groups of 3-6 participants each will be
      enrolled in the Phase I portion of the study, and up to 35 participants will be enrolled in
      Phase II.

      If you are enrolled in the Phase I portion, the dose of dasatinib you receive will depend on
      when you joined this study. The first group of participants will receive the lowest dose
      level of dasatinib. Each new group will receive a higher dose of dasatinib than the group
      before it, if no intolerable side effects were seen. If intolerable side effects are seen,
      the next group of participants may receive the same dose level or a lower dose level. This
      will continue until the highest tolerable dose of dasatinib is found.

      If you are enrolled in the Phase II portion, you will receive highest tolerated dose level of
      dasatinib that was found in the Phase I portion.

      All participants will receive the same dose level of erlotinib hydrochloride. If the doctor
      thinks it is needed, the dose level may be lowered.

      Study Drug Administration:

      If you are in Phase I, on Day -3 of Cycle 1 (3 days before your first dose of study drugs),
      you will take erlotinib hydrochloride by mouth. On Days 1-19 of Cycle 1, you will be take
      dasatinib and erlotinib hydrochloride by mouth once a day. On Days 20 and 21 of Cycle 1, you
      will only take dasatinib by mouth once a day. Every day of Cycles 2 and beyond, you will take
      dasatinib and erlotinib hydrochloride by mouth once a day.

      If you are in Phase II, every day you will take dasatinib and erlotinib hydrochloride by
      mouth once a day.

      Each cycle is 21 days.

      Erlotinib hydrochloride and dasatinib should be taken together at the same time every day.
      The tablets must be swallowed whole and may not be broken. The tablets should be taken with 1
      cup (about 8 ounces) of water. Dasatinib and erlotinib hydrochloride should be taken 1 hour
      before or 2 hours after meals or any other drugs, and should not be taken with grapefruit
      juice. The entire dose must be taken at 1 time. If you vomit within 30 minutes of swallowing
      the tablets, the dose may be replaced if the tablets can be seen and counted. If you are
      currently taking St. John's Wort, you should stopping taking if for at least 5 days before
      taking dasatinib.

      Study Visits:

      At Week 1 of Cycle 1, your vital signs and weight will be measured.

      At the end of Week 3 of every cycle, the following tests and procedures will be performed:

        -  You will have a physical exam, including measurement of your vital signs and weight.

        -  You will have a performance status evaluation.

        -  Blood (about 1 tablespoon) will be drawn for routine tests

        -  The amount of oxygen in your blood will be measured by a pulse oximeter.

        -  You will have a chest x-ray to check the status of the disease.

        -  You will be asked if you have experienced any side effects and to list any drugs you may
           be taking.

        -  Women who are able to become pregnant must have a negative blood (about 1-2 teaspoons)
           or urine pregnancy test.

      At the end of Week 3 of Cycles 1 and 3, you will also have an ECG.

      At the end of Week 3 of every other cycle (Cycles 2, 4, 6, and so on), you will also have a
      chest CT scan or a whole body PET/CT (if necessary) to check the status of the disease.

      Phase I PK Testing:

      If you are in Phase I, you will have blood (about 2 teaspoons each time) drawn for PK
      testing.

        -  On Day -3 of Cycle 1, blood will be drawn 5 different times.

        -  On Days -2, -1, and 1 of Cycle 1, blood will be drawn 1 time.

        -  On Day 19 of Cycle 1, blood will be drawn 5 times.

        -  On Days 20, 21, and 22 of Cycle 1, blood will be drawn 1 time.

      Length of Study:

      You may stay on study for as long as you are benefitting. You will be taken off study if you
      experience intolerable side effects or the disease gets worse.

      End-of-Study Visit:

      At the end of your study participation, you will have an end-of-study visit. At this visit,
      the following tests and procedures will be performed:

        -  You will have a physical exam, including measurement of your vital signs and weight.

        -  You will have a performance status evaluation.

        -  Blood (about 1 tablespoon) will be drawn for routine tests.

        -  The amount of oxygen in your blood will be measured.

        -  You will have a chest x-ray to check the status of the disease.

        -  You will have an ECG.

      If you are taken off study due to unacceptable side effects, you will be called and asked
      about any side effects until the side effect gets better or becomes stable.

      Long-Term Follow-Up:

      After the end-of-study visit, you will be contacted every 3-4 months for 1 year to collect
      information about how you are doing. You (or your family members or designees) may be
      contacted by telephone or during clinic visits. If you are called, this will take about 5
      minutes.

      This is an investigational study. Dasatinib is FDA approved and commercially available for
      the treatment of acute lymphoid and chronic myeloid leukemia. Erlotinib hydrochloride is FDA
      approved and commercially available for the treatment of non-small cell lung cancer. The use
      of this combination in this study is investigational.

      Up to 59 patients will take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Maximum Tolerable Dose (MTD) of Dasatinib Given With Erlotinib Hydrochloride</measure>
    <time_frame>Baseline and at Day 21</time_frame>
    <description>MTD defined as the highest dose level in which 6 patients have been treated with less than 2 instances of dose limiting toxicity (DLT). Dose-limiting toxicity (DLT) defined using NCI Common Terminology Common Terminology Criteria for Adverse Events (CTCAE) version 3 as: grade 3 or higher non-hematologic toxicity (excluding initial nausea and vomiting), grade 4 neutropenia, febrile neutropenia, or grade 4 thrombocytopenia. Grade 3-4 nausea and vomiting that cannot be controlled within 2 weeks with anti-emetics considered a DLT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II: Number of Participant With Response According to Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST criteria. Patients who have a partial or complete response or stable disease are defined as progression free. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): At least 30% decrease in sum of longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease (PD): At least 20% increase in sum of LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of one or more new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Progression-Free Survival (PFS) Rate</measure>
    <time_frame>12 Weeks</time_frame>
    <description>A modified Thall, Simon, and Estey (1995) design used in the phase II study to monitor the proportion of patients with NSCLC who are alive and progression free (PFS) at twelve weeks after commencing treatment with dasatinib and erlotinib.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasatinib + Erlotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Starting dose of 70 mg by mouth daily for 21 day cycle.</description>
    <arm_group_label>Phase I</arm_group_label>
    <other_name>BMS-354825</other_name>
    <other_name>Sprycel®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>150 mg by mouth daily every 21 day cycle.</description>
    <arm_group_label>Phase I</arm_group_label>
    <other_name>Erlotinib hydrochloride</other_name>
    <other_name>Tarceva</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Advanced malignancy that is appropriate for systemic therapy without curative intent.

          2. Patients must provide verbal and written informed consent indicating they are aware of
             the investigational nature of the study. Parental consent and patient assent is
             required for those aged 16-17.

          3. Patients must be at least 16 years of age.

          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

          5. Adequate hematologic, hepatic, and renal function as follows: creatinine &lt; 1.5 x the
             institutional upper limit of normal (ULN), total bilirubin &lt; 2.0 x ULN, AST and ALT &lt;
             2.5 x ULN, absolute granulocytes &gt;/= 1500/mm^3; platelets &gt;/= 75,000 mm^3; hemoglobin
             &gt;/= 10 g/dL.

          6. Serum potassium, magnesium, and phosphate within the institutional limits of normal.
             Patients with low potassium, phosphate, or magnesium levels may be repleted to allow
             for protocol entry.

          7. Serum calcium &gt;/= the institutional limits of normal. Patients with low calcium levels
             may be repleted to allow for protocol entry.

          8. Ability to take oral medication (dasatinib and erlotinib must be swallowed whole)

          9. Patients-both males &amp; females-w/reproductive potential must agree to use an adequate
             method of contraception to include hormonal contraceptives (birth control pills,
             injections, implants), intrauterine device (IUD), barrier contraceptive with
             spermicide, and/or abstinence throughout the study &amp; for at least 4 wks after the
             study drugs are stopped. Females w/ reproductive or childbearing potential include any
             female who has experienced menarche &amp; who has not undergone successful surgical
             sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is
             not postmenopausal

         10. -Continued from Inclusion #9 - [defined as amenorrhea &gt;/=12 consecutive mths;or women
             on hormone replacement therapy (HRT) w/ documented serum follicle stimulating hormone
             (FSH) level &gt; 35 milli-International unit (mIU)/mL]. Prior to study enrollment, women
             of childbearing potential must be advised of the importance of avoiding pregnancy
             during trial participation and the potential risk factors for an unintentional
             pregnancy.

         11. Women of childbearing potential must provide a negative pregnancy test (serum or
             urine) within 72 hours prior to the start of study drug administration.

         12. Asymptomatic brain metastases with prior cranial irradiation or resection are
             acceptable if there is no bleeding, no midline shift, and no need for steroids or
             anti-convulsants. Asymptomatic brain metastasis without prior treatment are acceptable
             if the largest lesion is less than 7 mm in diameter, there is no bleeding, midline
             shift, nor need for steroids or anti-convulsants.

         13. Patient agrees to discontinue St. Johns Wort at least 5 days before starting dasatinib
             or erlotinib.

         14. Patient agrees that IV bisphosphonates will be withheld for the first 8 weeks of
             dasatinib therapy due to risk of hypocalcemia.

         15. The patient's O^2 saturation must be &gt;92% on room air.

         16. (Phase II only) - Patient has never received prior therapy with dasatinib, or
             erlotinib, or another epidermal growth factor receptor (EGFR) or Src family kinase
             (SFK) inhibitor.

         17. (Phase I only) - Histological or unequivocal cytological proof of solid tumor
             malignancy.

         18. (Phase I only) - At least one prior systemic chemotherapy or biological therapy for
             recurrent or metastatic solid tumor (i.e., this protocol therapy must be administered
             as second line or greater), ), except if there is no standard or experimental systemic
             therapy available. If no effective systemic agent is available for first line therapy,
             then patients may be enrolled on the phase I as first line therapy.

         19. (Phase I only) - Prior radiotherapy is permitted (see exclusion criterion 4 for
             details on unallowable radiotherapy).

         20. (Phase II only) - Histological or unequivocal cytological proof of NSCLC.

         21. (Phase II only) - NSCLC that is appropriate for systemic therapy without curative
             intent: Stage IV, Stage IIIB with pleural effusion, or incurable recurrent disease
             after surgery or radiotherapy.

         22. (Phase II only) - Zero to one line of prior systemic therapy for recurrent or
             metastatic NSCLC. Prior adjuvant chemotherapy or adjuvant biologic therapy for NSCLC
             is not included as a line of prior therapy if it was completed greater than 3 months
             prior to recurrence, provided that the patient has never received any EGFR or SFK
             inhibitors.

         23. (Phase II only) - Measurable disease as defined by Response Evaluation Criteria in
             Solid Tumors (RECIST) criteria.

         24. (Phase II only) - Availability of tumor tissue that is at least adequate for EGFR
             mutational analysis. This can come from pre-existing paraffin blocks (from diagnostic
             biopsy or surgical resection) or patient may undergo a biopsy for research purposes.

         25. (Phase II only) - Prior radiotherapy is permitted as long as there is measurable
             disease outside of the radiotherapy port OR clearly recurrent and growing within the
             radiotherapy port (see exclusion criterion 2 for details on unallowable radiotherapy).

        Exclusion Criteria:

          1. Women who are pregnant, breastfeeding, or have child-bearing potential and are
             unwilling/unable to use an acceptable method of contraception for the entire study
             period and for at least 4 weeks after cessation of the study drugs. All women of
             child-bearing potential must have a negative pregnancy test prior to first receiving
             protocol therapy. If the pregnancy test is positive, the patient must not receive
             dasatinib or erlotinib, and must not be enrolled on the study

          2. Radiotherapy to ribs, sternum, pelvis, vertebrae or skull within 4 weeks prior to
             entering the study. (If none of these axial skeletal areas are included in the
             radiotherapy field, patients may have received palliative radiotherapy to long bones
             provided that it has ended at least 2 weeks prior to initiation of dasatinib-erlotinib
             therapy.)

          3. Patients with any of the following cardiac problems should be excluded: (a)
             Uncontrolled angina, congestive heart failure, or myocardial infarction within the
             previous 6 months; (b) Diagnosed congenital long QT syndrome; (c) Any history of
             clinically significant ventricular arrhythmias (such as ventricular tachycardia,
             ventricular fibrillation, or Torsades de pointes); (d) Prolonged [1] corrected QT
             interval (QTc) interval on pre-entry electrocardiogram (&gt; 450 msec in women or &gt;440
             msec in men). If the automated reading is prolonged, the ECG should be manually over
             read.

          4. Continued from Exclusion #4: (e) Any history of second or third degree heart block
             unless they currently have a pacemaker; (f) Heart rate &lt; 50 / minute on pre-entry
             electrocardiogram;(g) Uncontrolled hypertension defined as systolic blood pressure &gt;
             150 or diastolic &gt;100;(h) Subjects with hypokalemia or hypomagnesemia if it cannot be
             corrected prior to dasatinib administration.

          5. Patients with pericardial effusion &gt; grade 1 (by Common Toxicity Criteria for Adverse
             Effects (CTCAE) v3.0).

          6. Patients with pleural effusion &gt; grade 2 (by CTCAE v3.0). A grade 3 pleural effusion
             that is managed by a thoracentesis or an indwelling catheter is allowable as long as
             supplemental oxygen is not required.

          7. Patients with any condition that impairs their ability to swallow, retain, or absorb
             dasatinib or erlotinib tablets are excluded. This includes any condition resulting in
             an inability to take oral medication, a requirement for IV alimentation, prior
             surgical procedures that have resulted in chronic malabsorption, or active peptic
             ulcer disease.

          8. Patients with &gt; grade 2 neuropathy

          9. Patients with a history of pulmonary fibrosis (other than in a radiated field).

         10. Patients with inflammatory bowel disease or uncontrolled chronic diarrhea.

         11. Patients with a history of significant bleeding disorder unrelated to cancer,
             including: (a) Diagnosed congenital bleeding disorders (e.g., von Willebrand's
             disease); (b) Diagnosed acquired bleeding disorder within one year (e.g., acquired
             anti-factor VIII antibodies); (c) Ongoing or recent (&lt;/= 3 months) significant
             gastrointestinal bleeding, defined as clinically evident hematemesis or hematochezia
             requiring therapeutic intervention.

         12. Known HIV-positive patients are ineligible because of the potential for
             pharmacokinetic interactions between dasatinib and antiretroviral therapy. In
             addition, these patients are at increased risk of lethal infections when treated with
             marrow-suppressive therapy.

         13. Pts currently receiving any of the following medications will be excluded: (a) Any
             concurrent systemic anticancer therapy; (b) Any concurrent investigational agents (c)
             Category I drugs that are generally accepted to have a risk of causing Torsades de
             Pointes including: (Pts must discontinue such drugs 7 days or more prior to starting
             dasatinib):i. quinidine, procainamide, disopyramide;ii. amiodarone, sotalol,
             ibutilide, dofetilide;iii. erythromycin, clarithromycin;iv. chlorpromazine,
             haloperidol, mesoridazine, thioridazine, pimozide

         14. Continued from Exclusion#14:v.cisapride,bepridil,droperidol,methadone,arsenic,
             chloroquine,domperidone,halofantrine,levomethadyl,pentamidine,sparfloxacin,
             lidoflazine;(d)The concomitant use of H2 blockers or proton pump inhibitors w/
             dasatinib is not recommended.The use of antacids should be considered in place of H2
             blockers or proton pump inhibitors in pts receiving dasatinib therapy.If antacid
             therapy is needed,the antacid dose should be administered at least 2 hours prior to or
             2 hours after the dose of dasatinib.

         15. Continued from Exclusion #15: (e)Pt may not be receiving any prohibited CYP3A4
             inhibitors Potent inhibitors of CYP3A4 are prohibited during study; for such
             medications, a wash-out period of 7 days is required prior to starting dasatinib.
             Potent CYP3A4 inhibitors include: · itraconazole, ketoconazole, miconazole,
             voriconazole; amprenavir, atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir;
             ciprofloxacin, clarithromycin, diclofenac, doxycycline, enoxacin, imatinib, isoniazid,
             ketamine nefazodone, nicardipine, propofol, quinidine, telithromycin. (f) St.Johns
             Wort

         16. The patient has received prior investigational therapy, chemotherapy, radiotherapy, or
             major surgery within 3 weeks of initiating study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faye M. Johnson, MD, PhD, BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2009</study_first_submitted>
  <study_first_submitted_qc>January 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2009</study_first_posted>
  <results_first_submitted>September 18, 2015</results_first_submitted>
  <results_first_submitted_qc>September 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2015</results_first_posted>
  <last_update_submitted>May 26, 2016</last_update_submitted>
  <last_update_submitted_qc>May 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>Advanced Cancer</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Solid Tumor Malignancy</keyword>
  <keyword>Dasatinib</keyword>
  <keyword>BMS-354825</keyword>
  <keyword>Sprycel®</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>Erlotinib hydrochloride</keyword>
  <keyword>Tarceva</keyword>
  <keyword>OSI-774</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: February 6, 2008 to July 18, 2012. All recruitment done at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 53 participants registered, only 47 were eligible and treated. The study was terminated early due to futility.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dasatinib + Erlotinib</title>
          <description>Dasatinib orally starting dose 70 mg/day &amp; Erlotinib 150 mg orally/day every 21 day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Phase I</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Phase II</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dasatinib + Erlotinib: Phase I</title>
          <description>Dasatinib orally starting dose 70 mg/day &amp; Erlotinib 150 mg orally/day every 21 day cycle.</description>
        </group>
        <group group_id="B2">
          <title>Dasatinib + Erlotinib: Phase 2</title>
          <description>MTD from Phase I Dasatinib orally dose 70 mg/day &amp; Erlotinib 150 mg orally/day every 21 day cycle.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="47" upper_limit="74"/>
                    <measurement group_id="B2" value="63" lower_limit="44" upper_limit="89"/>
                    <measurement group_id="B3" value="62" lower_limit="44" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase I: Maximum Tolerable Dose (MTD) of Dasatinib Given With Erlotinib Hydrochloride</title>
        <description>MTD defined as the highest dose level in which 6 patients have been treated with less than 2 instances of dose limiting toxicity (DLT). Dose-limiting toxicity (DLT) defined using NCI Common Terminology Common Terminology Criteria for Adverse Events (CTCAE) version 3 as: grade 3 or higher non-hematologic toxicity (excluding initial nausea and vomiting), grade 4 neutropenia, febrile neutropenia, or grade 4 thrombocytopenia. Grade 3-4 nausea and vomiting that cannot be controlled within 2 weeks with anti-emetics considered a DLT.</description>
        <time_frame>Baseline and at Day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib + Erlotinib</title>
            <description>Dasatinib orally starting dose 70 mg/day &amp; Erlotinib 150 mg orally/day every 21 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase I: Maximum Tolerable Dose (MTD) of Dasatinib Given With Erlotinib Hydrochloride</title>
          <description>MTD defined as the highest dose level in which 6 patients have been treated with less than 2 instances of dose limiting toxicity (DLT). Dose-limiting toxicity (DLT) defined using NCI Common Terminology Common Terminology Criteria for Adverse Events (CTCAE) version 3 as: grade 3 or higher non-hematologic toxicity (excluding initial nausea and vomiting), grade 4 neutropenia, febrile neutropenia, or grade 4 thrombocytopenia. Grade 3-4 nausea and vomiting that cannot be controlled within 2 weeks with anti-emetics considered a DLT.</description>
          <units>mg/day</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Number of Participant With Response According to Response Evaluation Criteria in Solid Tumors (RECIST)</title>
        <description>Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST criteria. Patients who have a partial or complete response or stable disease are defined as progression free. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): At least 30% decrease in sum of longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease (PD): At least 20% increase in sum of LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of one or more new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase.</description>
        <time_frame>12 Weeks</time_frame>
        <population>One participant only received one day of therapy therefore was not evaluable for efficacy analyses; a second participant discontinued study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib + Erlotinib</title>
            <description>Dasatinib orally 70 mg/day &amp; Erlotinib 150 mg orally/day every 21 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Number of Participant With Response According to Response Evaluation Criteria in Solid Tumors (RECIST)</title>
          <description>Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST criteria. Patients who have a partial or complete response or stable disease are defined as progression free. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): At least 30% decrease in sum of longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease (PD): At least 20% increase in sum of LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of one or more new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase.</description>
          <population>One participant only received one day of therapy therefore was not evaluable for efficacy analyses; a second participant discontinued study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Progression-Free Survival (PFS) Rate</title>
        <description>A modified Thall, Simon, and Estey (1995) design used in the phase II study to monitor the proportion of patients with NSCLC who are alive and progression free (PFS) at twelve weeks after commencing treatment with dasatinib and erlotinib.</description>
        <time_frame>12 Weeks</time_frame>
        <population>Of the 35 participants in the Phase II portion of the study, one participant received one day of therapy therefore was not evaluable for efficacy analyses; a second participant discontinued study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib + Erlotinib</title>
            <description>Dasatinib orally 70 mg/day &amp; Erlotinib 150 mg orally/day every 21 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Progression-Free Survival (PFS) Rate</title>
          <description>A modified Thall, Simon, and Estey (1995) design used in the phase II study to monitor the proportion of patients with NSCLC who are alive and progression free (PFS) at twelve weeks after commencing treatment with dasatinib and erlotinib.</description>
          <population>Of the 35 participants in the Phase II portion of the study, one participant received one day of therapy therefore was not evaluable for efficacy analyses; a second participant discontinued study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event collection was through each 3 week treatment cycle, up to 12 weeks of assessment with treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dasatinib + Erlotinib</title>
          <description>Dasatinib orally starting dose 70 mg/day &amp; Erlotinib 150 mg orally/day every 21 day cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Blood/Bone Marrow</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Coagulation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="80" subjects_affected="34" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <description>INR - International Normalized Ratio of prothrombin time</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Lymphatics</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Cardiac General</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Cardiac pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QTc interval prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory/Ear</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hearing loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypoparathyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dry eye syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE3.0">Abdominal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Colitis, infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="40" subjects_affected="32" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="34" subjects_affected="30" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="55" subjects_affected="38" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="27" subjects_affected="14" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain (Other)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Infection (Other)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="23" subjects_affected="15" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="54" subjects_affected="24" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="26" subjects_affected="13" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory</sub_title>
                <counts group_id="E1" events="25" subjects_affected="11" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gait abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Neurology</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Mini mental status examination abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hemorrhage urinary tract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="34" subjects_affected="30" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="64" subjects_affected="34" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hemorrhage nasal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Laryngeal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Faye Johnson, Associate Professor, Thoracic/Head &amp; Neck Med Oncology</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

